Coverage of the 2017 IAS Conference on HIV Science
- Details
- Category: HIV Treatment
- Published on Monday, 31 July 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 9th International AIDS Society Conference on HIV Science, July 23-26, 2017, in Paris.
Antiretroviral Therapy
- Doravirine Combo Pill Looks Good for Initial HIV Treatment
- Boosted Darunavir Plus Lamivudine Matches 3-Drug Regimen
- Trans Women Wary of Antiretroviral Drug and Hormone Interactions
- Novel Long-Acting Drug Shows Promise for HIV Treatment and PrEP
- First Protease Inhibitor Combo Pill Maintains Viral Suppression
- Long-Acting Cabotegravir + Rilpivirine Looks Good for HIV ART
- New HIV Integrase Inhibitor Bictegravir Works Well for First-Line Treatment IAS
HIV Cure Research
- Cancer Research May Offer Clues for HIV Cure Research -- and Vice Versa
- Why Curing Cancer May Be Like Curing HIV -- and May Be As Difficult
- VRC01 Antibody Can Delay But Not Prevent HIV Rebound
- South African Child Has Controlled HIV Off Treatment for 8.5 Years
HIV Prevention
- Experts Agree that Intermittent Oral PrEP Probably Won't Work for Women
- Who Are Trans Women Acquiring HIV From?
- PrEP Use in U.S. Exceeds 100,000 in Gilead Pharmacy Survey
- Medical Male Circumcision for HIV Prevention Has Benefits for Women Too
- Another HIV Vaccine Efficacy Trial Will Start This Year
- Demonstration Projects Explore Feasibility of PrEP for Adolescents in South Africa
- Study of Gay Couples Shows No Transmissions from Undetectable HIV+ Partners
- Long-Acting Cabotegravir Shows Promise For HIV Prevention
- PrEP Still Protected People Who Had Less Sex in Ipergay Study
HIV-Related Conditions and Comorbidities
- Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV
- Acute Kidney Injury Uncommon on Tenofovir, No Link Seen to Bone Breaks
- People with HIV Are at Risk for Liver Fibrosis and Steatosis
HIV Epidemiology and Access to Care
- Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
- Improved Cryptococcal Meningitis Treatment Could Save Thousands of Lives
- WHO Recommends Urgent Care Package for People with Advanced HIV Disease
- World On Track To Reach 90-90-90 Targets for HIV Treatment by 2020
- New HIV Infections Halved as Treatment Scales Up in Swaziland
Hepatitis C and HIV/HCV Coinfection
- Glecaprevir/Pibrentasvir Effective for People with HIV/HCV Coinfection
- Hepatitis C Treatment is Effective and Feasible in Africa